Johnson & Johnson Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Johnson & Johnson (JNJ) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 92.90 million shares for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-07-23
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-06-28 was 92.90M shares, a 43.81% increase year-over-year.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-29 was 100.60M shares, a 45.80% increase year-over-year.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-28 was 124.30M shares, a 39.51% increase year-over-year.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-29 was 64.60M shares, a 3.19% increase year-over-year.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 124.10M shares, a 59.72% increase from fiscal 2024.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 77.70M shares, a 17.43% decline from fiscal 2023.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 94.10M shares, a 32.83% decline from fiscal 2023.
- Johnson & Johnson incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 140.10M shares, a 1.52% increase from fiscal 2022.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|---|
| 2026-06-28 | 92.90M shares 10-Q · filed 2026-07-23 | 96.70M shares 10-Q · filed 2026-07-23 | |||
| 2026-03-29 | 100.60M shares 10-Q · filed 2026-04-22 | ||||
| 2025-12-28 | 124.10M shares 10-K · filed 2026-02-11 | ||||
| 2025-09-28 | 124.30M shares 10-Q · filed 2025-10-22 | 89.30M shares 10-Q · filed 2025-10-22 | |||
| 2025-06-29 | 64.60M shares 10-Q · filed 2026-07-23 | 67.00M shares 10-Q · filed 2026-07-23 | |||
| 2025-03-30 | 69.00M shares 10-Q · filed 2026-04-22 | ||||
| 2024-12-29 | 77.70M shares 10-K · filed 2026-02-11 | ||||
| 2024-09-29 | 89.10M shares 10-Q · filed 2025-10-22 | 78.80M shares 10-Q · filed 2025-10-22 | |||
| 2024-06-30 | 62.60M shares 10-Q · filed 2025-07-24 | 79.30M shares 10-Q · filed 2025-07-24 | |||
| 2024-03-31 | 87.60M shares 10-Q · filed 2025-04-23 | ||||
| 2023-12-31 | 94.10M shares 10-K · filed 2026-02-11 | ||||
| 2023-10-01 | 119.20M shares 10-Q · filed 2024-10-23 | 96.90M shares 10-Q · filed 2024-10-23 | |||
| 2023-07-02 | 95.20M shares 10-Q · filed 2024-07-25 | 96.90M shares 10-Q · filed 2024-07-25 | |||
| 2023-04-02 | 0.00 shares 10-Q · filed 2024-05-01 | ||||
| 2023-01-01 | 140.10M shares 10-K · filed 2025-02-13 | ||||
| 2022-10-02 | 140.10M shares 10-Q · filed 2023-10-27 | 141.10M shares 10-Q · filed 2023-10-27 | |||
| 2022-07-03 | 143.70M shares 10-Q · filed 2023-07-31 | 141.80M shares 10-Q · filed 2023-07-31 | |||
| 2022-04-03 | 140.10M shares 10-Q · filed 2023-04-28 | ||||
| 2022-01-02 | 138.00M shares 10-K · filed 2024-02-16 | ||||
| 2021-10-03 | 138.30M shares 10-Q · filed 2022-10-27 | 139.10M shares 10-Q · filed 2022-10-27 | |||
| 2021-07-04 | 141.90M shares 10-Q · filed 2022-07-29 | 126.00M shares 10-Q · filed 2022-07-29 | |||
| 2021-04-04 | 128.40M shares 10-Q · filed 2022-04-29 | ||||
| 2020-09-27 | 115.70M shares 10-Q · filed 2021-10-29 | 120.20M shares 10-Q · filed 2021-10-29 | |||
| 2020-06-28 | 119.60M shares 10-Q · filed 2021-07-29 | 122.60M shares 10-Q · filed 2021-07-29 | |||
| 2020-03-29 | 126.00M shares 10-Q · filed 2021-04-30 | ||||
| 2019-09-29 | 117.80M shares 10-Q · filed 2020-10-23 | 137.60M shares 10-Q · filed 2020-10-23 | |||
| 2019-06-30 | 140.80M shares 10-Q · filed 2020-07-24 | 138.60M shares 10-Q · filed 2020-07-24 | |||
| 2019-03-31 | 136.70M shares 10-Q · filed 2020-04-29 | ||||
| 2018-09-30 | 140.30M shares 10-Q · filed 2019-10-28 | 140.90M shares 10-Q · filed 2019-10-28 | |||
| 2018-07-01 | 127.50M shares 10-Q · filed 2019-07-29 | 141.80M shares 10-Q · filed 2019-07-29 | |||
| 2018-04-01 | 139.50M shares 10-Q · filed 2019-05-01 | ||||
| 2017-10-01 | 139.30M shares 10-Q · filed 2018-10-31 | 141.20M shares 10-Q · filed 2018-10-31 | |||
| 2017-07-02 | 143.20M shares 10-Q · filed 2018-08-02 | 142.20M shares 10-Q · filed 2018-08-02 | |||
| 2017-04-02 | 141.20M shares 10-Q · filed 2018-05-01 | ||||
| 2016-10-02 | 140.80M shares 10-Q · filed 2017-11-02 | 144.00M shares 10-Q · filed 2017-11-02 | |||
| 2016-07-03 | 146.30M shares 10-Q · filed 2017-08-03 | 145.80M shares 10-Q · filed 2017-08-03 | |||
| 2016-04-03 | 145.70M shares 10-Q · filed 2017-05-08 | 144.40M shares 10-Q · filed 2016-05-10 | |||
| 2015-09-27 | 129.40M shares 10-Q · filed 2016-11-04 | 129.10M shares 10-Q · filed 2016-11-04 | |||
| 2015-06-28 | 151.40M shares 10-Q · filed 2016-08-04 | 151.40M shares 10-Q · filed 2016-08-04 | |||
| 2015-03-29 | 154.10M shares 10-Q · filed 2016-05-10 | ||||
| 2014-09-28 | 148.40M shares 10-Q · filed 2015-10-30 | 148.80M shares 10-Q · filed 2015-10-30 | |||
| 2014-06-29 | 154.80M shares 10-Q · filed 2015-07-31 | 155.20M shares 10-Q · filed 2015-07-31 | |||
| 2014-03-30 | 163.40M shares 10-Q · filed 2015-05-01 | ||||
| 2013-09-29 | 154.10M shares 10-Q · filed 2014-10-30 | 154.70M shares 10-Q · filed 2014-10-30 | |||
| 2013-06-30 | 162.50M shares 10-Q · filed 2014-08-01 | 163.00M shares 10-Q · filed 2014-08-01 | |||
| 2013-03-31 | 175.80M shares 10-Q · filed 2014-05-02 | ||||
| 2012-09-30 | 181.60M shares 10-Q · filed 2013-11-04 | 181.50M shares 10-Q · filed 2013-11-04 | |||
| 2012-07-01 | 138.10M shares 10-Q · filed 2013-08-01 | 138.00M shares 10-Q · filed 2013-08-01 | |||
| 2012-01-01 | 158.30M shares 10-K · filed 2012-02-23 | ||||
| 2011-10-02 | 165.00M shares 10-Q · filed 2011-11-08 | 164.70M shares 10-Q · filed 2011-11-08 | |||
| 2011-07-03 | 168.90M shares 10-Q · filed 2011-08-09 | 168.80M shares 10-Q · filed 2011-08-09 | |||
| 2011-04-03 | 138.50M shares 10-Q · filed 2011-05-10 | ||||
| 2011-01-02 | 156.10M shares 10-K · filed 2012-02-23 | ||||
| 2010-10-03 | 149.60M shares 10-Q · filed 2011-11-08 | 149.90M shares 10-Q · filed 2011-11-08 | |||
| 2010-07-04 | 175.50M shares 10-Q · filed 2011-08-09 | 175.40M shares 10-Q · filed 2011-08-09 | |||
| 2010-04-04 | 193.40M shares 10-Q · filed 2011-05-10 | ||||
| 2010-01-03 | 118.00M shares 10-K · filed 2012-02-23 | ||||
| 2009-09-27 | 174.50M shares 10-Q · filed 2010-11-10 | 103.90M shares 10-Q · filed 2010-11-10 | |||
| 2009-06-28 | 80.80M shares 10-Q · filed 2010-08-11 | 108.40M shares 10-Q · filed 2010-08-11 | |||
| 2008-12-28 | 179.00M shares 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |